ipragliflozin + Placebo + Pioglitazone
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus
Trial Timeline
Sep 15, 2010 → Apr 28, 2012
NCT ID
NCT01225081About ipragliflozin + Placebo + Pioglitazone
ipragliflozin + Placebo + Pioglitazone is a phase 3 stage product being developed by Astellas Pharma for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT01225081. Target conditions include Type 2 Diabetes Mellitus.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes Mellitus were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01225081 | Phase 3 | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus